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Results: Of 939/1077 (87%) HPV tested OPC, LDH level was 
available in 611/678 (90%) HPV+ and 225/261 (86%) HPV–. Median 
follow up was 4.4 and 4.1 years for the HPV+ and HPV– cohorts, 
respectively. Among HPV+, LDH E (n = 223) versus NE (n = 388) 
cases comprised older age (median 60 versus 58 years, p = 0.02) 
and slightly larger primary tumour volume (GTV) (median 24 
versus 21 cc, p = 0.08) but similar T (p = 0.27) and N-category 
(p=0.34), smoking pack-years (sPY) (p = 0.27), and alcohol 
consumption (p = 0.25). A lower three-year OS (79% versus 87%, 
p < 0.01) and RFS (79% versus 89%, p  < 0.01) were found in HPV+ 
LDH E versus NE. MVA for HPV+ patients confirmed that LDH-E 
increased risk of death [HR 1.5 (1.1-2.2), p = 0.03] and relapse 
[HR 1.8 (1.2-2.7), p < 0.01) after adjusting for sPY (OS: p < 0.01; 
RFS: p = 0.94), age (OS: p = 0.09; RFS: p = 0.63), T3-4 (OS: p = 
0.02; RFS: p = 0.48), N2c-3 (OS: p = 0.08; RFS: p < 0.01), GTV-1° 
(OS: p < 0.01; RFS: p < 0.01) and chemotherapy (OS: p < 0.01; 
RFS: p = 0.02). The prognostic significance of LDH-E was 
confirmed by MVA within the subset of HPV+ patients with normal 
liver function [OS: HR 1.7 (1.1-2.7), p = 0.01; RFS: 2.0 (1.3-3.3), 
p < 0.01]. RPA divided HPV+ OPC into low-risk (T1-3N0-N2c_LDH-
NE) and high-risk (T4 or N3 or T1-3N0-N2c_LDH-E) subgroups. The 
three-year OS was 91% versus 72% and RFS was 91% versus 75%, 
respectively (both p < 0.01). In the HPV– cohort, no differences 
were found in baseline characteristics or outcomes between LDH 
E (n = 86) and NE (n = 139) cases (three-year OS: 59% versus 52%, 
p = 0.96; RFS: 68% versus 68%, p = 0.91), and the non-prognostic 
effect was confirmed by MVA (OS: HR 1.2, p = 0.43; RFS: HR 1.1, 
p = 0.54) 
Conclusions: This study shows that pre-RT serum LDH elevation 
is prognostic for HPV+ OPC independent of liver function but non-
prognostic for HPV– patients. LDH has the potential to be 
included in HPV+ prognostic groupings, similar to other tumours. 
T1-3N0-N2c HPV+ OPC with elevated LDH appears associated 
with increased risk of death and disease relapse comparable to 
T4 or N3 subsets 
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Purpose: Breast-conserving surgery followed by adjuvant 
radiation therapy (RT) is the standard treatment for early-stage 
breast cancer (EBC). Up to 30% of patients experienced moist 
desquamation or ≥ Grade 2 skin toxicity following standard 
fractionation tangent field 3D-conformal radiotherapy (3D-CRT). 
The feasibility of skin-sparing helical tomotherapy (SSHT) by 
configuring skin as an organ at risk (OAR) was established in an 
earlier dosimetric study. The aim of this study was to assess 
whether SSHT would reduce the incidence of ≥Grade 3 acute skin 
toxicity in EBC patients undergoing RT. 
Methods and Materials: This single institution Phase III 
randomized control trial comparing SSHT to 3D-CRT for RT in EBC 
patients with acute skin toxicity as the primary endpoint. The 
skin as OAR was defined as a 5 mm strip of ipsilateral breast skin 
and we employed a constraint on the skin volume receiving dose 
up to 40 Gy while delivering dynamic IMRT as described earlier. 
Patients were assessed weekly during RT and then at six and 12 
weeks post-RT. Acute toxicity parameters recorded were level of 
skin erythema, radiation dermatitis, and pain. 
Results: During the period of May 2008 to January 2012, 177 EBC 
patients were enrolled into the study and 90 were randomized to 
3D-CRT arm and 87 to SSHT. The mean age was 59 years. SSHT 
achieved more homogenous coverage of the target than 3D-CRT. 
HT arm had lower proportion of acute toxicity. The incidence of 
erythema and moist desquamation were significantly higher in 
the 3D-CRT arm than in the SSHT treated arm (erythema: 60% 
versus 39%; p = 0.005; moist desquamation: 33% versus 11%; 
P=0.0003). No patients in the SSHT arm had exudate while 11% 
of patients in the 3D-CRT arm did (0% versus 11%; p = 0.0014). 
Patients in the 3D-CRT arm had increased incidence of ≥ Grade 3 
tenderness and discomfort of breast (tenderness: 54% versus 24%; 
p < 0.0001, discomfort: 9% versus 1%; p = 0.019), but ≥ Grade 3 
itching, burning and pulling were not significantly different 
between the treatment arms. The independent prognostic 
factors that contributed significantly to acute toxicity in the 
multivariate analysis were large breast volume, adjuvant 
chemotherapy, and 3D-CRT. 
Conclusions: SSHT significantly reduced the incidence of moist 
desquamation compared with 3D-CRT. Incidence of acute 
toxicity was correlated with large breast volume, adjuvant 
chemotherapy, and 3D-CRT. Combining an IMRT approach with 
explicit reduction in skin dose may further improve both acute 
and late skin toxicity for patients undergoing adjuvant breast 
radiotherapy.  
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THE ROLE OF STEREOTACTIC BODY RADIATION THERAPY (SBRT) 
IN GYNECOLOGICAL CANCERS: A SYSTEMATIC REVIEW 
Lucas C. Mendez1, Eric Leung2, Patrick Cheung2, Lisa Barbera2 
1University of São Paulo, São Paulo, Brazil 
2University of Toronto, Toronto, ON 
Purpose:  SBRT is an effective treatment that delivers highly 
conformal doses of radiation to target volumes, sparing normal 
organs. Despite the advancements in this technique for other 
disease sites, its role in gynecological cancers remains unclear. 
This systematic review aims to evaluate toxicity and outcomes 
of SBRT in gynecological malignancies. 
Methods and Materials: In accordance to PRISMA guidelines, 
a systematic review of the literature was conducted on 
studies reporting SBRT in gynecological malignancies. EMBASE, 
MEDLINE and Cochrane databases were systematically 
searched for relevant studies until October 2015. All 
relevant studies evaluating the role of local-regional SBRT 
for gynecological malignancies (excluding CNS, extra-pelvic 
and extra-para-aortic lesions) were included. Relevant data 
regarding toxicities and outcomes were abstracted and 
analyzed. 
Results: From 534 references, 23 articles from 2004 to 2015 were 
selected, comprising a total of 382 patients. Studies were 
classified into six categories: 1) Radical treatment with SBRT as 
local boost for cervix tumours: total of 34 patients were 
identified in seven studies. Treated PTV median volume (MV) 
ranged from 41 to 146 mL and local control (LC) from 0 to 100% 
in a median follow up time of 4 to 22 months. Gastro-intestinal 
(GI) G3/4 toxicity was ~12%. 2) Radical treatment with SBRT as 
a local boost for endometrial cancer: 13 patients found in three 
studies. Eighty-five percent of the patients were from one series 
reporting a 55% LC at 18 months. G3 GI toxicity was reported in 
one out of 13 patients. 3) SBRT to lymph node metastases: 197 
patients were found in seven studies. Treated PTV-MV ranged 
from 16 to 42 mL and LC 60-100% in a range of median follow up 
time of 14-20 months. Long-term G3/4 GI and genito-urinary 
(GU) toxicity was 3% and 0.005%, respectively. 4) Pelvic 
recurrences treated with SBRT: Majority received a course of 
radiotherapy before, either as a previous treatment or as first 
course on salvage attempt. Seventy-two patients were found in 
10 studies. Treated PTV-MV ranged from 20 to 154 mL and LC 
from 51% to 100% in a median follow up range of 4-22 months. 
Chronic G3/4 GI and GU toxicity were 22% and 1.5%, respectively. 
5) Adjuvant treatment with SBRT to the vaginal vault after EBRT:
61 patients were found in three studies. LC was 91-92% (1-11 
years) and GI G3 toxicity was 3%. 6) Two studies included two 
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patients with vaginal cancer and three with vulva cancer who 
received SBRT, either with radical or palliative intention. 
Conclusions: SBRT experience in gynecological tumours lacks 
homogeneity. Close to 400 patients treated with SBRT for 
locoregional disease were found in the literature and at least six 
different clinical scenarios were described. A high rate (> 20%) 
of late G3/4 GI toxicity was seen in patients with recurrent 
gynecological pelvic tumours when salvage was attempted with 
SBRT possibly due to multifactorial reasons. 
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Purpose: The ideal timing for post-implant dosimetry in 
permanent breast seed implant (PBSI) is yet unknown and is 
performed inconsistently across the country, limiting the ability 
to compare dosimetric indices among centres. The purpose of 
this study is to determine the most appropriate time to perform 
this post-implant analysis. 
Methods and Materials: Patients underwent four post-implant 
CT scans: 0, 15, 30, and 60 days after their seed implant. Each 
post-implant scan was deformably registered to the planning 
scan to obtain the seroma contour, which was reviewed and 
adjusted as necessary by a radiation oncologist. An evaluation 
PTV was defined to be a 5 mm isotropic expansion of the adjusted 
CTV contour, trimmed to the chest wall muscle and skin. 
Standard post-plans using the TG-43 calculation formalism were 
completed on each scan, considering dosimetric parameters for 
the CTV (V100) and evaluation PTV (V90, V100, and V200). As a 
reference, accumulated dose was determined by deformably 
summing the dose from all four time points to the day 0 post-
implant scan, taking into account the decay of the seeds to 
weight the dosimetric contribution from each time point. Each 
time point was compared to the reference accumulated dose by 
sum-of-squared residuals and absolute differences for each 
dosimetric index. 
Results: Five patients have completed all four post-implant CT 
scans. The PTV V200 showed the most significant disagreement 
between the accumulated dose and each individual postplan 
(median absolute disagreement: 7.3%, range: 0.7 – 16.8%), while 
the CTV V100 showed fairly consistent agreement for all time 
points (median absolute disagreement: 0.5%, range: 0.0 – 5.3%). 
The day 15 scan showed the smallest sum-of-squared residuals 
for both the CTV V100 and the PTV V200; 51% and 52% lower than 
the next best time point, respectively, when considering the 
entire cohort. Other time points, however, still showed similar 
CTV V100 values, while other dosimetric indices had more 
variation in both time and between individual patients. 
Conclusions: For the five patients who have completed all four 
requisite scans, the PTV V200 showed the largest variation when 
compared to the reference accumulated dose, while the CTV 
V100 had fairly good agreement for all time points. The time 
point which best agrees with the reference accumulated dose is 
not unanimous for all patients; further patient accrual is ongoing 
and required to recommend the most appropriate time point for 
the population. 
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FOR DIFFERENT PARTS OF THE PROCESS  
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Purpose: At the Allan Blair Cancer Centre, we began real-time 
ultrasound-guided prostate HDR on May 13, 2015. Starting with 
our third case, we began monitoring various time points during 
the procedure to see how long different parts took and whether 
there was reduction in times as the number of cases increased. 
Methods and Materials: Several time points were recorded for 
each case including the "Time Out" before anesthetic induction, 
TRUS insertion, placement of first needle, start of contouring, 
start of needle reconstruction, start of plan QA, start of 
treatment and start of needle removal. The experience in 
number of cases performed by each team member was also 
monitored. Members involved over the period of study included 
three physicists, four radiation therapists, three radiation 
oncologists and five radiation therapy nurses as well as a number 
of anesthesiologists from the health region. Treatment planning 
was performed by two physicists and two radiation therapists. 
Results: For cases 3 to 27, the average overall time from "Time 
Out" to catheter removal was 3 hours 45 minutes. The longest 
part of the process was for needle reconstruction and treatment 
planning, with an average time of 1 hour 9 minutes. Using a linear 
fit to the data for these 25 consecutive cases, the overall time 
decreased by 21 minutes, or about 9%. This is primarily due to a 
decrease of 17 minutes in needle reconstruction and planning 
time and a decrease of seven minutes in anesthetic induction 
time. The trends for other times varied by less than four minutes. 
Discussion: We observed a significant decrease in the time for 
needle reconstruction and treatment planning with the number 
of cases performed. This is likely due to increased familiarity 
with the planning system and looking at ultrasound images as 
well as improved needle placement preventing shadowing of one 
needle by another. The reason for the decrease in anesthetic 
induction time is likely better preparation (making sure the carts 
are functioning and stocked and calling for an endotracheal 
scope early in cases that might require one). These are important 
factors when doing anesthetic procedures outside the OR with 
many different anesthesiologists. 
Conclusions: Over 25 consecutive cases, we saw a decrease in 
total time for real-time ultrasound-guided prostate HDR of 9%, 
with the largest factor being a decrease in the time for needle 
reconstruction and treatment planning. We will continue to 
monitor our process and will also look at correlating times with 
the experience levels of individual team members. 
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Purpose: To evaluate biochemical disease-free survival rates and 
toxicity in patients treated with combined EBRT and HDR 
brachytherapy boost. 
Methods and Materials: We reviewed data for men with prostate 
cancer treated with EBRT and brachytherapy boost from 2010 to 
2014 in one centre. From 2010-2012 patients were treated with 
50 Gy in 20 fractions of EBRT with a 10Gy HDR boost. From 2012-
2014 patients were treated with 44 Gy in 22 fractions of EBRT 
and 15 Gy EBRT boost. From 2014 onwards 37.5 Gy in 15 fractions 
combined with 15 Gy brachytherapy boost was used. 
Results: One hundred and sixty-five consecutive patients treated 
from 2010 to 2014 were evaluated. Median age was 67. 4% (n = 
6) had low-risk prostate cancer, 76% (n = 125) had intermediate-
risk and 20% (n=34) had high-risk disease. Twenty-seven percent 
(n = 44) received 50 Gy+10 Gy boost, 49% (n = 81) received 44 Gy 
+ 15 Gy boost and 24% (n = 40) received 37.5 Gy + 15 Gy boost. 
Fifty percent had brachytherapy prior to EBRT and the other 50% 
had brachytherapy after EBRT. Thirty-five percent received 
androgen deprivation therapy. Actuarial Biochemical Disease-
Free Survival (Phoenix definition) was 89% at five years (100%, 
87% and 100% respectively for low-, intermediate- and high-risk). 
